Status:
COMPLETED
Intensity Modulated Radiation Therapy - Gyne Cancer (GY03.2)
Lead Sponsor:
University Health Network, Toronto
Collaborating Sponsors:
Princess Margaret Hospital, Canada
Conditions:
Cervix Neoplasms
Uterine Neoplasms
Eligibility:
FEMALE
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
Standard treatment for gynecological cancer is radiation therapy in two phases; whole pelvic radiation and then an internal radiation boost, also called a brachytherapy boost, to treat any remaining t...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Biopsy-proven carcinoma of the cervix, uterus or vagina; FIGO stage T1B-4A, NO/1, MO, treated with definitive radiotherapy with or without chemotherapy, or Biopsy-proven pelvic recurrence of carcinoma of the uterus previously untreated or biopsy-proven vaginal carcinoma treated radically with radiotherapy but unsuitable for brachytherapy boost.
- Patients not suitable for intracavitary brachytherapy.
- ECOG performance status of 0, 1, or 2
- Age ≥ 18 years
- Ability to give informed consent.
Exclusion
Key Trial Info
Start Date :
June 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2014
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT00188578
Start Date
June 1 2003
End Date
June 1 2014
Last Update
February 9 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Princess Margaret Hospital
Toronto, Ontario, Canada, M5G 2M9